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POOLED EFFICACY AND SAFETY FROM PHASE 3 PLACEBO-
CONTROLLED STUDIES OF TANEZUMAB IN PATIENTS WITH
OSTEOARTHRITIS
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Inc., New York, NY, USA; z Stamford Therapeutics Consortium, Stamford, CT,
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Purpose: Nerve growth factor (NGF) is a key mediator of pain signaling.
Tanezumab (TNZ) is a humanized monoclonal antibody with high
selectivity and speciﬁcity for NGF. TNZ signiﬁcantly reduces pain and
improves physical function and patient’s global assessment in patients
with chronic pain. From June 2010 to August 2012 the US Food and Drug
Administration imposed a partial clinical hold on noncancer pain-
related TNZ studies due to unexpected adverse events initially reported
as osteonecrosis that required total joint replacement. A prospective
analysis was conducted to evaluate the efﬁcacy and safety of TNZ with
severe symptomatic osteoarthritis (OA).
Methods: Four, phase 3 placebo (PBO)-controlled clinical trials of TNZ in
patients with moderate-to-severe OA of the knee or hip which com-
pleted before the clinical hold were pooled for evaluating efﬁcacy in
patients with severe OA (deﬁned as those with baseline Western
Ontario andMcMasters Universities Osteoarthritis [WOMAC] pain score
7 [on 11-point numeric rating scale], WOMAC physical function score
of 7, and score of “poor” or “very poor” in the Patient’s Global
Assessment [PGA] of OA). Nine phase 3 controlled OA studies were
pooled to evaluate safety. Patients received 1 to 3 injections of intra-
venous TNZ 2.5, 5, or 10 mg every 8 weeks, naproxen 500 mg twice
daily, or PBO. Efﬁcacy was assessed as 3 co-primary endpoints: WOMAC
pain, WOMAC physical function, and PGA of OA; percentages of patients
with 30%, 50%, 70%, and 90% improvement on the WOMAC Pain
subscale were secondary endpoints. Safety assessments included
adverse event documentation, physical and neurologic examinations,
and laboratory tests. Patients who reported abnormal peripheral sen-
sation and/or had clinically signiﬁcant neurological exam ﬁndings
underwent neurological consultation.
Results: In the overall population in the 4 studies, TNZ 2.5-10 mg
provided signiﬁcant improvement over PBO in the 3 co-primary end-
points and percentages of patients with pain reduction 30%, 50%,
70%, and 90%. Of the 2979 patient enrolled across the 4 studies, 742
(25.1%) met the criteria for severe OA. TNZ 5 and 10 mg provided sig-
niﬁcant and clinically meaningful beneﬁt versus PBO in the severe
patient subgroup across the 3 co-primary endpoints (p0.001; Figure).
Signiﬁcantly more patients treated with TNZ 5 or 10 mg reported pain
reduction 30%, 50%, 70%, and 90% than PBO-treated patients
(p0.05 for all). Incidence of adverse events, withdrawals due to
adverse events, and serious adverse events in patients treated with TNZ
was similar to patients receiving active comparator and increased over
PBO-treated patients; rates with TNZ 5 and 10 mg were similar and
elevated versus TNZ 2.5 mg. Adverse events of abnormal peripheral
sensation were more frequently reported by patients receiving TNZ
versus patients receiving PBO or active comparator. A majority of TNZ-
treated patients whose ﬁnal neurological consultations were catego-
rized as having a new or worsening peripheral neuropathy based on
clinically signiﬁcant signs or diagnostic tests were diagnosed with some
form of mononeuropathy, predominantly carpal tunnel syndrome or
radiculopathy; few patients were diagnosed with a polyneuropathy.
TNZ 10mg but not 2.5 or 5mgwas associatedwith higher rate of rapidly
progressive OA than active comparator.Conclusions: TNZ provides signiﬁcant improvement of pain, physical
function, and PGA of OA. In patients with severe OA at baseline, TNZ
provided signiﬁcant and clinically meaningful beneﬁt. Non-joint-rela-
ted safety was similar in patients treated with TNZ 2.5-10mg to patients
receiving active comparator although rates of adverse events were
increased versus PBO-treated patients. Supported by Pﬁzer Inc.
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Purpose: Selecting medications to manage severe and persistent pain
associated with osteoarthritis (OA) involves assessing comparative
beneﬁts and harms of non-steroidal anti-inﬂammatory drugs (NSAIDs)
and opioid analgesics. Few studies have compared these agents rigor-
ously. The goal of this study is to summarize the comparative effec-
tiveness of oral NSAIDs and opioids in reducing pain for persons with
knee OA.
Methods: Two reviewers independently screened reports of random-
ized controlled trials, published in English between 1982 and 2014, that
evaluated the most commonly prescribed oral NSAIDs or opioids for
knee OA.We included studies that were at least eight weeks in duration,
conducted in Western Europe, the Americas, New Zealand or Australia,
and that presented baseline and follow-up pain data using the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain
subscale, which we converted to a 0-100 scale (100 worst). The primary
outcome was the mean change in pain, adjusted to account for study
withdrawals due to lack of efﬁcacy. Using a random effects analysis to
account for heterogeneity, we calculated a ﬁnal combined estimate of
change in pain for each treatment regimen. We conducted a meta-
regression analysis to examine factors associated with greater efﬁcacy
of oral analgesia. The independent variable of primary interest was the
treatment regimen (NSAIDs vs. less potent opioids vs. potent opioids).
The meta-regression adjusted for percent of the cohort with knee OA
(vs. hip), percent of the cohort that was female, study year, and country
(exclusively US-based vs. all other).
Results: Twenty-ﬁve distinct treatment arms (14 NSAIDs [8 celecoxib, 4
diclofenac, 2 naproxen], 7 less potent opioids [6 tramadol and 1 tra-
madol/acetaminophen], and 4 potent opioids [2 hydromorphone and 2
oxycodone]) were included in the analysis. Trial duration ranged from 8
to 26 weeks; median duration was 12.5 weeks for NSAID treatment
arms and 12.0 weeks for opioid treatment arms (p[[Unsupported Char-
acter - Codename :]]¼0.015). The size of the treatment arms varied from
25 to 481 (median 235) persons for NSAID arms and from 60 to 201
(median 153) persons for opioid arms (p¼0.041). Baseline patient
demographics were similar for NSAID and opioid arms. Subjects in
groups taking NSAIDs reported lower median baseline WOMAC Pain
than subjects in groups taking opioids (56 and 61, respectively,
p¼0.041) and slightly shorter median time-since-diagnosis (6.1 years
and 7.7 years, respectively; p¼0.088). NSAID studies reported lower
median proportion of subjects withdrawing due to toxicity compared to
opioid studies (6.5% vs. 25.9%, p¼0.002) and similar median proportion
of subjects withdrawing due to insufﬁcient efﬁcacy (7.4% vs. 8.8%,
p¼0.478). After adjusting for efﬁcacy-related withdrawals, the eval-
uated drug classes were associated with similar pain reductions
(NSAIDs: -18.2 [SE 1.2]; less potent opioids: -19.6 [SE 1.4] potent
opioids: -19.9 [SE 1.1]) (Figure). The meta-regression analysis did not
reveal differential effectiveness by treatment regimen, but found that
treatment groups with a higher proportion of male subjects and worse
baseline pain experienced greater pain reductions across all regimens
evaluated.
Conclusions: NSAIDs and opioids offer similar pain reduction in per-
sons with OA. The attenuated analgesic effect of opioids may be
explained by more severe pain at study onset, prior exposure to a
greater number of failed regimens, and longer duration of symptoms.
Given the similar efﬁcacy proﬁles of the different medications, the
prescription of these analgesics to knee OA patients should be consid-
ered primarily from the view of their respective toxicity proﬁles and
patients’ prior medication histories.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A356Figure. Adjusted mean change from baseline in WOMAC Pain for NSIADs,
less potent opioids, and potent opioids.
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Purpose: Previous studies have suggested that placebo injections
into the knee joint can relieve pain in patients with knee osteo-
arthritis (KOA). It is now clear that several different types of pain
and pain mechanisms can occur in KOA: some patients have sig-
niﬁcant pain sensitisation, and a generalised pain problem compli-
cating any peripheral, nocioceptive cause. It is also known that some
20% of people who have a knee replacement do not obtain good pain
relief. We wanted to investigate the possible value of an intra-
articular injection of either a placebo or a local anaesthetic as an aid
to sorting out pain mechanisms, and helping patients and
their doctors decide whether surgery might be a good treatment
option.
Methods: The study was approved by the local ethics committee. 20
patients attending a rheumatology clinic because of bilateral, painful
KOA were recruited and gave signed, informed consent. Demographic
data was collected, including a full pain history, and the knees were
examined. Each patient then had two injections into the knee which
was causing them most pain (the index knee), with an interval of two
weeks between each injection. They were randomised to having intra-
articular Marcaine or an equivalent volume of saline ﬁrst, and the
alternative injection second, in a double blind study design. Prior to
each injection pain questionnaires were administered, including the s-
LANSS to assess neuropathic pain, and the HADs to assess the degree of
anxiety and depression. Following each injection pain scores were
collected daily in relation to both knees, for a two week period. 3
months after the end of the study all patients were recalled for follow-
up at which point they were asked about their satisfactionwith being in
the study, their preference for the ﬁrst or second injection, the overall
amount of symptom relief, whether the contralateral knee had
improved during the study, and whether being in the study had helped
them understand their pain better and decide whether surgery was for
them or not.
Results: 13 women and 7 men were recruited to the study, 14 were
Caucasian, 4 Indian and 2 Samoan, their mean age was 63 years (range
47-81). All were on some medication for their painful knee OA (18
simple analgesics, 14 NSAIDs) and they were suffering from a variety of
co-morbidities. Baseline scores indicated that 7 were complaining of
widespread pain problems in addition to knee pain, 4 had s-LANSS
scores of 12 or greater indicative of neuropathic-like pain, and 3 had a
high HADs score indicative of signiﬁcant anxiety/depression.10 patients
had Marcaine ﬁrst and 10 Saline ﬁrst. Most patients reported some pain
relief after each injection, but there were no signiﬁcant differences in
pain scores after the Marcaine or Saline: pain relief was greater after
Marcaine than Saline in 7 people, greater after Saline than Marcaine in8, and in the remaining 5 the pain relief scores were almost identical
after each injection. The total pain scores at the end of each two week
observation period showed that scores were lower at the end of the
second period than at the end of the ﬁrst, irrespective of whether
Marcaine or Saline was injected ﬁrst, and at the three month assess-
ment 13 said they favoured the second injection and 7 the ﬁrst. Four
patients reported improvement in pain in the contralateral knee. There
was no apparent difference in the response to Saline or Marcaine in
those with or without widespread pain, neuropathic pain, or anxiety/
depression. However, satisfaction with the study did differ in these
groups: fewer of those with widespread pain, neuropathic pain and
anxiety or depression reported that they got better than those without
any such features (5 of 9 compared with 9 of 11 respectively). 19 or the
20 said they were pleased to have had the chance to take part, 13 said
that it had helped greatly with their understanding of their pain
problem and 9 said it had inﬂuenced their decision about surgical
intervention.
Conclusions: There was very little difference in the pain response to
intra-articular Marcaine or Saline in this small pilot placebo study of
intra-articular injections in patients with KOA. This suggests that much
of the response to any intra-articular therapy is placebo related. The
study is too small to reach any conclusions about the value of this
approach in sorting out different pain syndromes, but we believe it
likely that it could be a helpful research tool, and out data strongly
suggest that it can be a valuable aid to doctors and patients in gaining
understanding of the pain, and in coming to appropriate treatment
decisions.
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RANDOMIZED CONTROLLED TRIALS
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Purpose: Curcuminoids are natural products with potent anti-inﬂam-
matory and antioxidant properties. There have been a number of
reports on the analgesic effects of curcuminoids in clinical trials, yet
data have not been fully conclusive. The objective of this study was to
provide the highest level of evidence on the efﬁcacy of curcuminoids in
patients with painful conditions through meta-analysis of data from
randomized controlled trials (RCTs).
Methods: A systematic review and meta-analysis was conducted using
data reported by RCTs. The primary efﬁcacy measure was pain intensity
or algofunctional status. Treatment effect was summarized with
standardized mean difference (SMD) calculated from differences in
means of pain measures between treatment and control groups using a
random-effects model.
Results: A total of 8 RCTs met our inclusion criteria, that included 606
randomized patients with diffrent painful conditions (osteoarthritis,
rheumatoid arthritis, ﬁbromyalgia). Curcuminoids were found to sig-
niﬁcantly reduce pain (SMD: -0.57, 95% CI: -1.11 to -0.03, p ¼ 0.04). This
pain-relieving effect was found to be independent of administered dose
and duration of treatment with curcuminoids, and was free from pub-
lication bias. Curcuminoids were safe and well tolerated in all evaluated
RCTs.
Conclusions: This meta-analysis of RCTs showed that supplementation
with curcuminoids is a safe and effective strategy to reduce pain severity.
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TRADITIONAL CHINESE MEDICINE FOR OSTEOARTHRITIS PAIN: A
META-ANALYSIS
B. Chen y, C. Lo z, H. Zhan y, X. Lin y, C. Wang z. y Shuguang Hosp. afﬁliated
to Shanghai Univ. of Traditional Chinese Med., Shanghai, China; z Tufts
Med. Ctr., Boston, MA, USA
Purpose: The history of oral Chinese herbal medicine is ancient, and the
therapy is considered to have analgesic effects for patients with knee
osteoarthritis (OA). We conducted a systematic review and meta-
analysis of the evidence to evaluate the efﬁcacy for pain relief of oral
Chinese herbal medicine in patients with knee OA.
